Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Brief Summary: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.


Options:
A: Arm Label: Safety Run-in Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab | Arm Label: Obinutuzumab + Venetoclax; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax, Drug: Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Obinutuzumab + Chlorambucil | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Obinutuzumab + Chlorambucil, Obinutuzumab + Venetoclax, Safety Run-in Obinutuzumab + Venetoclax
B: Arm Label: Treatment Arm A: Ibrutinib and Venetoclax (I+VEN); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Venetoclax, Drug: Ibrutinib (as Subsequent Therapy) | Arm Label: Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab, Drug: Ibrutinib (as Subsequent Therapy) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Ibrutinib (as Subsequent Therapy); Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN), Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)
C: Arm Label: obinutuzumab + chlorambucil (GClb); Type: EXPERIMENTAL; Interventions: Drug: obinutuzumab, Drug: chlorambucil | Arm Label: rituximab + chlorambucil (RClb); Type: ACTIVE_COMPARATOR; Interventions: Drug: rituximab, Drug: chlorambucil | Arm Label: Chlorambucil (Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil | Intervention Type: DRUG; Name: obinutuzumab; Assigned to Arm(s): obinutuzumab + chlorambucil (GClb) | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): rituximab + chlorambucil (RClb) | Intervention Type: DRUG; Name: chlorambucil; Assigned to Arm(s): Chlorambucil (Clb), obinutuzumab + chlorambucil (GClb), rituximab + chlorambucil (RClb)
D: Arm Label: Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Arm Label: Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Ibrutinib | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Chlorambucil

Answer: D